R&D DAYS 1/5: IR Conference Call on Phase 2b BTKi (‘168) Trial Results

Sanofi hosted on April 23, 2020 a live webcast and conference call on the detailed Phase 2b results of the investigational BTK inhibitor ('168) in relapsing multiple sclerosis.

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies